Literature DB >> 1649111

Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes.

N Rojansky1, U Halbreich, K Zander, A Barkai, S Goldstein.   

Abstract

Gonadal hormones are believed to be involved in the pathophysiology of premenstrual changes (PMC) possibly through their interaction with neurotransmitter systems in the brain. The serotonergic system, an important central modulator of mood and behavior which is involved in the pathophysiology of affective disorders has been suggested to play a role in the genesis of dysphoric PMC. Blood platelet serotonin (5-HT) uptake and imipramine (IMI) binding have been shown to share similarities with serotonergic mechanisms in the brain thus enabling the study of serotonergic mechanisms. In this study, we report on platelet 5-HT uptake and IMI receptor binding which were simultaneously studied in women with PMC. Subjects with PMC showed a large interindividual variability with no consistent typical pattern or change during the late symptomatic as compared to the early nonsymptomatic luteal phase. Their IMI receptor binding, however, was lower compared to controls already during the early luteal phase before they developed symptoms and was similar during the symptomatic phase. This might suggest a preexistent vulnerability to the development of dysphoric PMC that might be related to impaired gonadal hormone modulation of the serotonergic system.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1649111     DOI: 10.1159/000293135

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  13 in total

Review 1.  The pathophysiologic background for current treatments of premenstrual syndromes.

Authors:  Uriel Halbreich
Journal:  Curr Psychiatry Rep       Date:  2002-12       Impact factor: 5.285

2.  Combined Oral Contraceptive Pill Initiation in a Patient With Major Depressive Disorder, Premenstrual Dysphoric Disorder, Social Anxiety, Panic Disorder, and Histrionic Personality Disorder.

Authors:  Cody Roi; Erich J Conrad
Journal:  Ochsner J       Date:  2017

Review 3.  Premenstrual syndrome and premenstrual dysphoric disorder: guidelines for management.

Authors:  M Steiner
Journal:  J Psychiatry Neurosci       Date:  2000-11       Impact factor: 6.186

Review 4.  The role of central serotonergic dysfunction in the aetiology of premenstrual dysphoric disorder: therapeutic implications.

Authors:  B L Parry
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

5.  Striatal dopamine transporter availability with [123I]beta-CIT SPECT is unrelated to gender or menstrual cycle.

Authors:  Susan E Best; Philip M Sarrel; Robert T Malison; Marc Laruelle; Sami S Zoghbi; Ronald M Baldwin; John P Seibyl; Robert B Innis; Christopher H van Dyck
Journal:  Psychopharmacology (Berl)       Date:  2005-11-09       Impact factor: 4.530

Review 6.  Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder.

Authors:  Ellen W Freeman
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 7.  Update on research and treatment of premenstrual dysphoric disorder.

Authors:  Joanne Cunningham; Kimberly Ann Yonkers; Shaughn O'Brien; Elias Eriksson
Journal:  Harv Rev Psychiatry       Date:  2009       Impact factor: 3.732

8.  Premenstrual Dysphoric Disorder: Recognition and Treatment.

Authors:  Ellen W. Freeman; Steven J. Sondheimer
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-02

9.  Premenstrual syndrome.

Authors:  Kimberly Ann Yonkers; P M Shaughn O'Brien; Elias Eriksson
Journal:  Lancet       Date:  2008-04-05       Impact factor: 79.321

10.  The premenstrual syndrome and fibromyalgia--similarities and common features.

Authors:  Daniela Amital; Calanit Herskovitz; Leah Fostick; Alysa Silberman; Yariv Doron; Joseph Zohar; Alek Itsekson; Matityahu Zolti; Alan Rubinow; Howard Amital
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.